Dr. Erika Hamilton spoke with CURE’s editor-in-chief, Dr. Joshua K. Sabari.
Highlights in ER-positive breast cancer from SABCS 2025 include key metastatic and early-stage trial results from AMBRE, ...
HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...
At the San Antonio Breast Cancer Symposium (SABCS), investigators outlined the rationale and design of the ERADICATE, a first ...
TipRanks on MSN
FDA clears Abpro’s lead HER2 cancer drug for phase 1
The latest update is out from Abpro Holdings ( (ABP) ).
Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and ...
SurvivorNet on MSN
Enhertu significantly cuts recurrence rates for women with high-risk HER2-positive breast cancer — the practice-changing DESTINY-Breast05 trial
DESTINY-Breast05 is a large phase 3 trial in women with HER2-positive early-stage breast cancer who had chemotherapy and ...
Investigator sought to compare treatment strategies that omit chemotherapy and/or include ribociblib against standard treatment for safety and efficacy.
Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...
Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback